Table 1.
Patient and Tumor Characteristics
| Characteristics | Patients (n=60) | Percentage (%) |
|---|---|---|
| No. of men | 49 | 81.7 |
| No. of women | 11 | 18.3 |
| Mean age (y) | 61.0 ± 12.8 | |
| Median tumor size (cm) | 2.3 (1.5–3.0) | |
| Gross tumor volume (cm3) | 16.0 (5.2–43.2) | |
| Biologically effective dose (Gy) | 96.0 (86.4–100.0) | |
| Pre-treatment red blood cell (x1012/L) | 4.58 ± 0.53 | |
| Pre-treatment neutrophil count (x109/L) | 3.5 (2.7–4.2) | |
| Pre-treatment platelet count (x109/L) | 120.5 ± 59.9 | |
| Pre-treatment lymphocyte count (x109/L) | 1.35 ± 0.55 | |
| Post-treatment neutrophil count (x109/L) | 3.0 (2.4–4.1) | |
| Post-treatment platelet count (x109/L) | 111.0 ± 57.5 | |
| Post-treatment lymphocyte count (x109/L) | 0.69 ± 0.30 | |
| Child-Pugh classification A | 60 | 100 |
| Type of chronic hepatitis | 44 | 73.3 |
| Hepatitis B | 43 | 71.7 |
| Hepatitis C | 1 | 1.7 |
| Previous treatments | 45 | 75.0 |
| Surgery treatment | 19 | 31.7 |
| TACE or RFA or PEI | 31 | 51.7 |
| No. of lesions | ||
| 1 | 57 | 95.0 |
| 2 | 3 | 5.0 |
| SBRT-related toxicity | ||
| Grade 2 | 2 | 3.3 |
| Grade 3 | 1 | 1.7 |
Notes: Unless otherwise noted, data were numbers with percentages, or medians, with interquartile ranges in parentheses, except for age, pre-treatment red blood cell, pre- and post- treatment lymphocyte count and platelet count, which were presented as mean ± standard deviation.
Abbreviations: TACE, transarterial chemoembolization; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; SBRT, stereotactic body radiation therapy.